Frontlight ResearchEarly access
Not yet recruitingPhase 1
A Phase 1 Study of FXR0906 in Healthy Adults With or Without Elevated Triglycerides
Key facts
- Who runs it
- Fosun Pharmaceutical Industrial Development (Shenzhen) Co., Ltd.
- Where
- China1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Not yet recruiting
- Phase
- Phase 1
- People taking part
- 24 people, planned
- Started
- 25 Aug 2026
- Expected to end
- 20 Dec 2027
- Type of study
- Interventional, 3 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- Intervention1: FXR0906 injection
- Intervention2: FXR0906 injection
- Placebo
- Record updated
- 14 August 2026
Who can take part
- Age
- 18 years to 55 years
- Sex
- Women and men
- Healthy volunteers
- Can take part
The registry criteria, word for word
Show all 8 criteriaShow less
Who can take part
- Males or females aged ≥18 and ≤55 years at the time of screening; 2. Body mass index (BMI) ≥18.0 and ≤35.0 kg/m² at the time of screening, with female participants weighing >45 kg and male participants weighing >50 kg; 3. Fasting serum triglyceride (TG) level TG > 80 mg/dL (0.90 mmol/L) during screening; 4. Fasting LDL-C level ≥ 70 mg/dL (1.81 mmol/L) during screening; Exclusion criteria: 1. History or presence of clinically significant diseases/abnormality, or with clinically significant symptoms/signs, or self-reported diseases, unsuitable for enrollement in the judgement of the investigator
- Fasting blood glucose ≥7.0 mmol/L or HbA1c ≥6.5% during screening. 3. Use of any lipid-lowering treatment (e.g., drugs lowering LDL-C or TG), including but not limited to statins, ezetimibe, fibrates, omega-3 fatty acids, nutritional supplements, or other treatment regimens altering serum lipids within 30 days prior to screening, or use of any ASO or siRNA therapies lowering serum lipids within 12 months prior to screening
- Use of investigational drugs or instruments within 3 months prior to screening , or plans to participate in other clinical trials during this study. 5. Clinical laboratory parameters during screening meeting any of the following criteria:
- ALT and/or AST >1.5 × ULN
- ALT and/or AST > ULN and ≤1.5 × ULN, deemed clinically significant and unsuitable for participation in the clinical trial by the investigator
- INR > ULN, deemed clinically significant and unsuitable for participation in the clinical trial by the investigator
- Estimated glomerular filtration rate (eGFR) <90 mL/min/1.73 m2 (using MDRD formula)
- Other examination abnormalities deemed clinically significant and unsuitable for participation in the clinical trial by the investigator
The main criteria, as questions
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 55 years old?
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
This is a phase 1, randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics effects of a single dose of FXR0906 injection or placebo in Chinese healthy adult volunteers with or without TG increase.
The 3 groups in the trial
- Arm1: FXR0906 injectionTreatment being tested
Dose 1 of FXR0906 injection
Treatment: Intervention1: FXR0906 injection
- Arm2: FXR0906 injectionTreatment being tested
dose 2 of FXR0906 injection
Treatment: Intervention2: FXR0906 injection
- Arm3: placebo comparator: placeboPlacebo, for comparison
placebo
Treatment: Placebo
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Single-Center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of FXR0906 in Healthy Adult Participants With or Without Elevated Triglycerides
- Criteria questions
- Built from NCT07766759, who can take part
- Record updated
- 14 August 2026